|
|
Pacira Biosciences inc (PCRX) |
|
|
|
Pacira Biosciences Inc 's Yearly Income from Continued Operations Growth 5 Years |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
PCRX Annual Income from Cont. Operations Growth |
2022
|
2021
|
2019
|
2018
|
2017
|
Y / Y Annual Income from Cont. Operations Change |
-62.1 % |
- |
- |
- |
- |
Annual Income from Cont. Operations (in millions $) |
$15.91 |
$41.98 |
$-11.02 |
$-2.04 |
$-47.48 |
Annual Income from Cont. Operations Growth
Comment |
Pacira Biosciences Inc experienced detoriation of Annual Income from Cont. Operations for the fiscal year ended 2022 by -62.1% to $ 15.91 millions, compare to $ 41.98 in Annual Income from Cont. Operations reported in the previous year. Pacira Biosciences Inc 's Income from Continued Operations decline slowed form -481.08 % contraction in the fiscal year 2021.
Pacira Biosciences Inc Annual Income Statement
|
You need to upgrade your Flash Player
|
Companies with similar 2022 Annual Income from Cont. Operations within Healthcare Sector | Y/Y Income from Continued Operations Growth % | 2022 Annual Income from Cont. Operations | Sinovac Biotech Ltd | -99.39 % | $ 88.131 millions | Fulgent Genetics Inc | -71.97 % | $ 141.923 millions | Uniqure N v | | | |